BlueRock Therapeutics is a biotechnology company headquartered in New York City, New York that was founded by Lorenz Studer, Gordon Keller, Michael Laflamme, and Viviane Tabar.
BlueRock is using their Cell plus Gene platform to produce cell therapies for replacement of damaged or degenerated tissue. BlueRock’s neurology pipeline focuses on Parkinson’s Disease and engineering microglia for other neurological disorders. Their cardiology pipeline includes cell therapy for heart failure using cardiomyocytes. For autoimmune diseases, the company is designing macrophage cell therapies. BlueRock is using ex vivo engineering to enable cells to produce enzymes, antibodies and other proteins with therapeutic benefit.
Cell therapy candidates are based on induced pluripotent stem (IPS) cell technology. The company’s approach is based on iPSC intellectual property invented by Shinya Yamanaka of Kyoto University in Japan and licensed from iPS Academia Japan, which manages iPSC IP.
BlueRock has partnerships with Memorial Sloan Kettering Cancer Center and Toronto-based Centre for Commercialization of Regenerative Medicine (CCRM).
In December 2018, BlueRock partnered with The McEwen Stem Cell Institute at the University Health Network (UHN) in Toronto’s MaRS Discovery District. A new pilot Good Manufacturing Practices (GMP) facility will open in 2019.
On December 12, 2016 BlueRock Therapeutics completed their series A funding round with $225 million in funding from Versant Ventures and Bayer AG.
Timeline
DE) is paying up to $600 million for full control of cell therapy developer BlueRock Therapeutics, stepping up investment in a promising new medical area to revive its drug development pipeline. Having established BlueRock as part of a 2016 joint venture with Versant Ventures, Bayer will acquire the remaining 59.2% stake for about $240 million upfront and an additional $360 million depending on certain development achievements, it said on Thursday.
Funding Rounds
Patents
Further Resources
$225M BlueRock Therapeutics "monster" a magnet for Canada's biotech sector
Financial Post
News
BlueRock Therapeutics Strengthens Collaboration with the McEwen Stem Cell Institute
BlueRock Therapeutics
Web
BlueRock Therapeutics: A regenerative medicine game-changer
Invest Ontario
Web
What You Need to Know About BlueRock Therapeutics
Mark Terry
Web